See analyst estimates and all valuation multiples for Genomics & Personalized Medicine
| Company | EV | EV/LTM Revenue | EV/LTM EBITDA |
|---|---|---|---|
| $21.6B | 11.1x | -87.4x | |
| $17.3B | 4.0x | 15.1x | |
| $10.3B | 3.4x | 25.0x | |
| $8.0B | 9.4x | -34.4x | |
| $3.6B | 9.7x | 85.6x | |
| $2.6B | 2.9x | 16.6x | |
| $2.6B | 4.5x | 52.7x | |
| $2.1B | 4.4x | 19.5x | |
| $1.5B | 4.2x | -12.7x | |
| $1.3B | 2.1x | -9.4x | |
| $1.1B | 1.9x | 18.0x | |
| $778M | 4.9x | -4.4x | |
| $749M | 2.4x | 14.2x | |
| $706M | 11.4x | n/a | |
| $654M | 84.8x | -3.6x | |
| $628M | 4.6x | -0.8x | |
| $611M | 0.7x | 18.8x | |
| $549M | 73.5x | -5.4x | |
| $473M | 1.3x | 16.3x | |
| $389M | n/a | n/a | |
| $365M | 1.2x | -29.1x | |
| $344M | 1.1x | 8.3x | |
| $334M | 90.0x | n/a | |
| $305M | 17.8x | n/a | |
| $277M | 3.6x | -3.7x | |
| $239M | n/a | n/a | |
| $231M | n/a | -1.5x | |
| $217M | 52.1x | -23.1x | |
| $203M | 2.9x | -5.0x | |
| $196M | 4.0x | -2.7x | |
| $196M | 4.0x | -1.8x | |
| $169M | n/a | n/a | |
| $161M | 58.4x | -8.6x | |
| $160M | 2.4x | -3.2x | |
| $139M | 35.7x | n/a | |
| $131M | n/a | -1.4x | |
| $130M | n/a | -1.3x | |
| $115M | 4.7x | -0.6x | |
| $108M | 10.9x | -0.6x | |
| $67.2M | 13.4x | -0.5x | |
| $60.8M | 1.2x | 8.9x | |
| $45.7M | 0.7x | n/a | |
| $26.3M | 2.7x | -0.2x | |
| $22.7M | 0.7x | -0.5x | |
| $15.1M | n/a | n/a | |
| $13.4M | 0.5x | -0.3x | |
| $9.4M | n/a | -0.1x | |
| $8.9M | n/a | n/a | |
| $0.9M | n/a | n/a | |
| -$4.0M | n/a | 0.0x | |
| -$7.8M | -4.0x | 0.1x | |
| -$10.8M | n/a | n/a | |
| -$13.7M | -0.9x | n/a | |
| -$56.0M | -0.8x | n/a | |
| -$92.2M | -2.3x | 1.0x |
Valuation multiples as of last 12 months (LTM). Financial data powered by Morningstar, Inc.
See analyst estimates and M&A multiples for Genomics & Personalized Medicine